Regeneron Pharmaceuticals Statistics
Total Valuation
REGN has a market cap or net worth of $53.86 billion. The enterprise value is $38.94 billion.
| Market Cap | 53.86B |
| Enterprise Value | 38.94B |
Important Dates
The next estimated earnings date is Thursday, July 31, 2025, before market open.
| Earnings Date | Jul 31, 2025 |
| Ex-Dividend Date | May 20, 2025 |
Share Statistics
REGN has 105.67 million shares outstanding. The number of shares has increased by 0.13% in one year.
| Current Share Class | 103.85M |
| Shares Outstanding | 105.67M |
| Shares Change (YoY) | +0.13% |
| Shares Change (QoQ) | -2.28% |
| Owned by Insiders (%) | 5.44% |
| Owned by Institutions (%) | 90.13% |
| Float | 99.75M |
Valuation Ratios
The trailing PE ratio is 12.93 and the forward PE ratio is 14.08. REGN's PEG ratio is 1.84.
| PE Ratio | 12.93 |
| Forward PE | 14.08 |
| PS Ratio | 3.89 |
| Forward PS | 3.88 |
| PB Ratio | 1.84 |
| P/TBV Ratio | 1.91 |
| P/FCF Ratio | 17.36 |
| P/OCF Ratio | 13.62 |
| PEG Ratio | 1.84 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 8.71, with an EV/FCF ratio of 12.55.
| EV / Earnings | 8.65 |
| EV / Sales | 2.76 |
| EV / EBITDA | 8.71 |
| EV / EBIT | 9.80 |
| EV / FCF | 12.55 |
Financial Position
The company has a current ratio of 4.93, with a Debt / Equity ratio of 0.09.
| Current Ratio | 4.93 |
| Quick Ratio | 3.90 |
| Debt / Equity | 0.09 |
| Debt / EBITDA | 0.60 |
| Debt / FCF | 0.87 |
| Interest Coverage | 83.17 |
Financial Efficiency
Return on equity (ROE) is 15.96% and return on invested capital (ROIC) is 8.04%.
| Return on Equity (ROE) | 15.96% |
| Return on Assets (ROA) | 6.91% |
| Return on Invested Capital (ROIC) | 8.04% |
| Return on Capital Employed (ROCE) | 11.70% |
| Revenue Per Employee | $932,457 |
| Profits Per Employee | $297,849 |
| Employee Count | 15,106 |
| Asset Turnover | 0.39 |
| Inventory Turnover | 2.44 |
Taxes
In the past 12 months, REGN has paid $484.90 million in taxes.
| Income Tax | 484.90M |
| Effective Tax Rate | 9.73% |
Stock Price Statistics
The stock price has decreased by -50.95% in the last 52 weeks. The beta is 0.31, so REGN's price volatility has been lower than the market average.
| Beta (5Y) | 0.31 |
| 52-Week Price Change | -50.95% |
| 50-Day Moving Average | 558.53 |
| 200-Day Moving Average | 744.35 |
| Relative Strength Index (RSI) | 41.15 |
| Average Volume (20 Days) | 1,598,608 |
Short Selling Information
The latest short interest is 2.70 million, so 2.55% of the outstanding shares have been sold short.
| Short Interest | 2.70M |
| Short Previous Month | 2.80M |
| Short % of Shares Out | 2.55% |
| Short % of Float | 2.70% |
| Short Ratio (days to cover) | 1.81 |
Income Statement
In the last 12 months, REGN had revenue of $14.09 billion and earned $4.50 billion in profits. Earnings per share was $39.43.
| Revenue | 14.09B |
| Gross Profit | 6.87B |
| Operating Income | 3.98B |
| Pretax Income | 4.78B |
| Net Income | 4.50B |
| EBITDA | 4.47B |
| EBIT | 3.98B |
| Earnings Per Share (EPS) | $39.43 |
Balance Sheet
The company has $8.35 billion in cash and $2.70 billion in debt, giving a net cash position of $14.92 billion or $141.21 per share.
| Cash & Cash Equivalents | 8.35B |
| Total Debt | 2.70B |
| Net Cash | 14.92B |
| Net Cash Per Share | $141.21 |
| Equity (Book Value) | 29.39B |
| Book Value Per Share | 277.50 |
| Working Capital | 14.01B |
Cash Flow
In the last 12 months, operating cash flow was $3.95 billion and capital expenditures -$851.30 million, giving a free cash flow of $3.10 billion.
| Operating Cash Flow | 3.95B |
| Capital Expenditures | -851.30M |
| Free Cash Flow | 3.10B |
| FCF Per Share | $29.35 |
Margins
Gross margin is 48.80%, with operating and profit margins of 28.22% and 31.94%.
| Gross Margin | 48.80% |
| Operating Margin | 28.22% |
| Pretax Margin | 35.38% |
| Profit Margin | 31.94% |
| EBITDA Margin | 31.74% |
| EBIT Margin | 28.22% |
| FCF Margin | 22.02% |
Dividends & Yields
This stock pays an annual dividend of $1.76, which amounts to a dividend yield of 0.35%.
| Dividend Per Share | $1.76 |
| Dividend Yield | 0.35% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 4.46% |
| Buyback Yield | -0.13% |
| Shareholder Yield | 0.21% |
| Earnings Yield | 8.35% |
| FCF Yield | 5.76% |
Analyst Forecast
The average price target for REGN is $854.26, which is 67.59% higher than the current price. The consensus rating is "Buy".
| Price Target | $854.26 |
| Price Target Difference | 67.59% |
| Analyst Consensus | Buy |
| Analyst Count | 23 |
| Revenue Growth Forecast (5Y) | 4.97% |
| EPS Growth Forecast (5Y) | 9.34% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
REGN has an Altman Z-Score of 9.55 and a Piotroski F-Score of 3.
| Altman Z-Score | 9.55 |
| Piotroski F-Score | 3 |